Semaglutide vs. Tirzepatide: Which GLP-1 Medication Is Right for You?
GLP-1 medications have transformed medically supervised weight management, but choosing between semaglutide and tirzepatide isn't always straightforward. Both work. Both produce meaningful weight loss. The differences come down to mechanism, average results, cost, and which fits your medical history. Here is an honest, evidence-based comparison.
Devorah, DNP, APRN, FNP-BC
Board-Certified Nurse Practitioner · Bee the NP
What is semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk for type 2 diabetes (marketed as Ozempic) and later approved at higher doses specifically for chronic weight management (Wegovy). It works by mimicking the natural GLP-1 hormone your gut releases after eating. That mimicry binds GLP-1 receptors in the pancreas, stomach, and brain, suppressing appetite, slowing gastric emptying, and regulating blood sugar.
In the STEP 1 clinical trial, adults on semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% on placebo. Participants also saw significant improvements in blood pressure, blood sugar, and lipid panels. Semaglutide is administered as a once-weekly subcutaneous injection, starting at 0.25mg and titrated up over 16–20 weeks to the full 2.4mg therapeutic dose.
What is tirzepatide?
Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual GIP + GLP-1 receptor agonist developed by Eli Lilly. It's the first approved medication to activate both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) pathways simultaneously. GIP is another incretin hormone that enhances insulin secretion, promotes fat storage in healthy subcutaneous tissue rather than visceral organs, and appears to amplify the appetite-suppressing effects of GLP-1.
In the SURMOUNT-1 trial, adults on tirzepatide 15mg weekly lost an average of 22.5% of body weight over 72 weeks. That's the highest average weight loss ever recorded in a pharmaceutical trial for obesity. At the 10mg dose, average weight loss was 19.5%. These numbers represent a meaningful difference from semaglutide in head-to-head comparisons. Tirzepatide is also titrated slowly over 20 weeks, starting at 2.5mg weekly.
Head-to-head: How do the results compare?
The SURMOUNT-5 trial directly compared tirzepatide to semaglutide in adults with obesity (without diabetes). At 72 weeks, tirzepatide 15mg produced approximately 47% more weight loss than semaglutide 2.4mg (an average of 20.2% vs. 13.7% body weight reduction). Tirzepatide also resulted in more patients achieving ≥20% weight loss (32% vs. 16%).
That said, both medications produce clinically significant weight loss that would be nearly impossible to achieve through lifestyle modification alone. Individual responses vary considerably: some patients lose more on semaglutide than the average tirzepatide user. Factors including insulin resistance, cortisol patterns, baseline GIP sensitivity, and adherence all influence outcomes. For patients who have tried semaglutide without adequate response, switching to tirzepatide often produces additional results.
Side effects: Are they different?
Both medications share the same class of GI side effects: nausea, constipation, vomiting (especially during dose increases), and occasional diarrhea. These effects are dose-dependent and typically most prominent during the titration phase. Slow, careful titration, exactly the kind of oversight Devorah provides, dramatically reduces the severity of GI symptoms.
In clinical trials, GI side effects occurred in similar proportions for both medications. Some patients find tirzepatide's nausea profile slightly more manageable due to the GIP mechanism moderating GI motility. Both carry an FDA boxed warning about a theoretical risk of medullary thyroid carcinoma (based on animal data, not confirmed in humans), which is why neither medication is appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Which medication should you choose?
For most patients seeking maximum weight loss efficacy, tirzepatide's clinical trial data is compelling, and it has become the preferred option when access and cost are equal. For patients who have already started semaglutide and are responding well, there is no reason to switch. For patients who have tried semaglutide without adequate response, tirzepatide is an excellent next step.
Cost and insurance coverage are significant practical considerations. Wegovy and Zepbound carry similar list prices (around $1,300–$1,500/month), though manufacturer coupons, prior authorization, and formulary placement vary. Compounded versions of both are available through licensed pharmacies for those without coverage, though quality and potency must be verified. Devorah reviews your full medical history, prior weight loss history, and goals to recommend the most appropriate medication and dose for you.
Key takeaways
- Semaglutide produces ~15% average weight loss; tirzepatide produces ~20–22% in clinical trials
- Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates GLP-1 only
- GI side effects are similar for both; slow titration is the key to tolerability
- Both medications require medical supervision and ongoing oversight
- Individual response varies: your best result depends on your metabolic profile
- Devorah prescribes both and will help you determine which is right for your situation
Talk to Devorah
Free 15-minute discovery consult. No obligation, just real answers to your questions.
Book free consultRelated services
Free consultation
Ready to take the next step?
Book a free 15-minute discovery consult with Devorah and get a personalized plan, not a generic recommendation.